ACS CAN and more than 150 organizations representing patients, providers and health equity advocates sent a letter to Congress urging them to pass the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act into law to remove barriers to clinical trial enrollment.
Health Equity in Biomarker Testing and Targeted Therapy
Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, currently not all individuals benefit equitably from these advances. There are notable racial/ethnic, and socioeconomic disparities in access and utilization of these advancements in care. These disparities in access and use of guideline-indicated biomarker testing and targeted therapy can potentially widen existing disparities in cancer survival.